3 Undervalued Biotechnology Stocks for Thursday, October 03
Discover the top 3 undervalued Biotechnology stocks for Thursday, October 03 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Commentary & Analysis
3 Undervalued Medical Equipment, Supplies & Distribution Stocks for Monday, September 02
Discover the top 3 undervalued Medical Equipment, Supplies & Distribution stocks for Monday, September 02 based on AAII’s Stock Grades.Omar Beirat
3 Undervalued Medical Equipment, Supplies & Distribution Stocks for Wednesday, July 31
Discover the top 3 undervalued Medical Equipment, Supplies & Distribution stocks for Wednesday, July 31 based on AAII’s Stock Grades.Omar Beirat
4 Undervalued Medical Equipment, Supplies & Distribution Stocks for Monday, July 01
Discover the top 4 undervalued Medical Equipment, Supplies & Distribution stocks for Monday, July 01 based on AAII’s Stock Grades.Grace Malone
5 Undervalued Medical Equipment, Supplies & Distribution Stocks for Wednesday, May 22
Discover the top 5 undervalued Medical Equipment, Supplies & Distribution stocks for Wednesday, May 22 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.1 | $286.3 | 1% |
|
| Shares Out (Mil) | 1.8 | 54.2 | 7% |
|
| Institutional Ownership | 94.1% | 92.8% | 64% |
|
| Float (Mil) | 1.8 | 39.7 | 5% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,674 | 534 | 79% |
|
| Price Change (52-week) |
(73.1%) | 58.7% | 8% |
|
| Growth | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (11.5%) | (10.1%) | 28% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.190) | ($1.230) | ($0.670) | |
| Month Ago EPS | ($0.180) | ($1.170) | ($0.640) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.360) | ($1.930) | ($1.260) | |
| Year/Year Chg | (55.9%) | (53.5%) | na | |
| Financials | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($3) | ($43) | 35% |
|
| EPS (TTM) | ($1.605) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($31) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($3) | $160 | 3% |
|
| Valuation | BBLG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.28 | 2.77 | 4% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (50.5%) | (47.3%) | 11% |
|
| ROE | (55.0%) | (55.0%) | 14% |
|
| Liabilities to Assets | 11.5% | 29.6% | 7% |
|
| F-Score | 2 | 2 | 7% |
|
Bone Biologics Corporation did not pass any screens on 8/20/2026.
